Table of Content

Recent Advancement in Cancer Molecular Signaling

Submission Deadline: 30 September 2022 (closed)

Guest Editors

Professor Francesco Marotta, ReGenera International for Aging Intervention, Milano, Italy
Professor Antonio Ayala, Department of Biochemistry and Molecular Biology, University of Seville, Spain
Professor Roberto Catanzaro, Department of Clinical and Experimental Medicine, Gastroenterology Section, University of Catania, Italy

Summary

It is well-known in clinics that different oncological subjects respond differently to the same drug, due to the wide number of specific gene sequence of proteins involved in the response to drug therapy. This area is further complicated by the fact that most genes have different statutary and epigenomic characteristics in different individuals. The study of this discipline not only is constantly unveiling specific molecular signaling which the onset and progression of cancer can be advocate for, but also offer the tremendous opportunity for a pharmacogenomics-driven specific approach. With the advancement and affordability of new generation sequencing and molecular signaling monitoring, an ever increasing number of cancer pathways are nowadays under scrutiny. At the same time, the study of polymorphic variants of genes responsible for the metabolism, transport, absorption, distribution and excretion of the drugs, is helping zooming down to define sinest regulatory mechanisms based on which to design putative modulators. This holds true also to delineate genes and their isoform regulation of enzymes responsible for the metabolism of many commonly prescribed cancer drugs so to calculate, foresee and ideally prevent major side effects of a given compound.

 

In the present special issue, we welcome researchers actively working in this area, to submit their most recent and relevant findings aiming to the quest of an ever improving cancer understanding and approach. For all of them, BIOCELL does represent an ideal platform to present their data with relevant visibility and trigger fruitful scientific discussion.

 



Keywords

Molecular Signaling, Modulators and Regulators of Signaling, Lung Cancer, Hepatocellular Cancer, Breast Cancer, ENT Cancer, Solid Cancers

Published Papers


  • Open Access

    ARTICLE

    Glucocorticoid reduces the efficacy of afatinib on the head and neck squamous cell carcinoma

    DONGYANG WANG, YI CHEN, JING HUANG, YOU ZHANG, CHONGKUI SUN, YINGQIANG SHEN
    BIOCELL, Vol.47, No.2, pp. 329-338, 2023, DOI:10.32604/biocell.2023.023489
    (This article belongs to this Special Issue: Recent Advancement in Cancer Molecular Signaling)
    Abstract Glucocorticoids (GC) are widely used to counter the adverse events during cancer therapy; nonetheless, previous studies pointed out that GC may reduce the efficacy of chemotherapy on cancer cells, especially in epidermal growth factor receptor (EGFR)-targeted therapy of head and neck squamous cell carcinoma (HNSCC) remaining to be elucidated. The primary aim of the present study was to probe into the GC-induced resistance of EGFR-targeted drug afatinib and the underlying mechanism. HNSCC cell lines (HSC-3, SCC-25, SCC-9, and H-400) and the human oral keratinocyte (HOK) cell lines were assessed for GC receptor (GR) expression. The promoting tumor growth effect of… More >

  • Open Access

    ARTICLE

    The transcriptome analysis of cleft lip/palate-related PTCH1 variants in GMSM-K cells show carcinogenic potential

    MINGZHAO LI, QIAN ZHANG, WENBIN HUANG, SHIYING ZHANG, NAN JIANG, XIAOSHUAI HUANG, FENG CHEN
    BIOCELL, Vol.47, No.1, pp. 205-214, 2023, DOI:10.32604/biocell.2022.022572
    (This article belongs to this Special Issue: Recent Advancement in Cancer Molecular Signaling)
    Abstract Cancer progression involves the sonic hedgehog (SHH) pathway, in which the receptor PTCH1 actives the downstream pathways. Dysfunction of PTCH1 can lead to nevoid basal cell carcinoma Syndrome (NBCCs) including neoplastic disease and congenital disorder. To evaluate the relationship between PTCH1 and cancer, we applied the CRISPR/Cas9 system to knock out PTCH1 in oral nontumorous epithelial cells (GMSM-K). Then we screened six PTCH1 variants associated with cleft lip/palate (CL/P), one of the congenital disorders in NBCCs, and generated PTCH1 variant and wild-type recombinant PTCH1−/− GMSM-K cell lines. Transcriptome sequencing was conducted in these cell lines. The results revealed that differentially… More >

  • Open Access

    REVIEW

    Effect of demethyltransferase FTO on tumor progression

    LING SHENG, YUEHONG SHEN, HONGYU YANG
    BIOCELL, Vol.46, No.11, pp. 2387-2397, 2022, DOI:10.32604/biocell.2022.021032
    (This article belongs to this Special Issue: Recent Advancement in Cancer Molecular Signaling)
    Abstract N6-methyladenosine (m6A) modification is the most widespread and conserved internal mRNA modification in mammalian cells. It greatly affects genetic regulation by enhancing the involvement of diverse cellular enzymes and thus, plays a significant role in basic life processes. Numerous studies on m6A modification identified FTO as a crucial demethylase that participates in various biological processes. Not only does FTO play a pivotal role in obesity-related conditions, but it also influences the occurrence, development, and prognosis of several cancers, such as acute myeloid leukemia, breast cancer, liver cancer, and lung cancer. Moreover, FTO also shows a close association with immunity and… More >

  • Open Access

    ARTICLE

    3-epi-bufotalin suppresses the proliferation in colorectal cancer cells through the inhibition of the JAK1/STAT3 signaling pathway

    SANHUA LI, QINGHONG KONG, XIAOKE ZHANG, XINTING ZHU, CHUNBO YU, CHANGYAN YU, NIAN JIANG, JING HUI, LINGJIE MENG, YUN LIU
    BIOCELL, Vol.46, No.11, pp. 2425-2432, 2022, DOI:10.32604/biocell.2022.019916
    (This article belongs to this Special Issue: Recent Advancement in Cancer Molecular Signaling)
    Abstract Traditional Chinese medicine (TCM) has been increasingly employed in the last decades in China for both preventing and treating a variety of cancers. 3-epi-bufotalin is an active ingredient of TCM “Chanpi” with anti-tumor potential. However, the effect and mechanism of 3-epi-bufotalin on colorectal cancers were not well disclosed. The present study demonstrated that 3-epi-bufotalin could reduce viability, trigger apoptosis, and block the cell cycle at the G2/M stage in colorectal cancer cell lines HT29, RKO, and COLO205 in vitro. Moreover, 3-epi-bufotalin inhibited the JAK1/STAT3 signaling pathway. These results indicated the anti-proliferation ability of 3-epi-bufotalin in colorectal cancer cells. More >

  • Open Access

    REVIEW

    Navigating the genomic instability mine field of osteosarcoma to better understand implications of non-coding RNAs

    KANIZ FATEMA, ZACHARY LARSON, JARED BARROTT
    BIOCELL, Vol.46, No.10, pp. 2177-2193, 2022, DOI:10.32604/biocell.2022.020141
    (This article belongs to this Special Issue: Recent Advancement in Cancer Molecular Signaling)
    Abstract Osteosarcoma is one of the most genomically complex cancers and as result, it has been difficult to assign genomic aberrations that contribute to disease progression and patient outcome consistently across samples. One potential source for correlating osteosarcoma and genomic biomarkers is within the non-coding regions of RNA that are differentially expressed. However, it is unsurprising that a cancer classification that is fraught with genomic instability is likely to have numerous studies correlating non-coding RNA expression and function have been published on the subject. This review undertakes the formidable task of evaluating the published literature of non-coding RNAs in osteosarcoma. This… More >

  • Open Access

    VIEWPOINT

    Biomarkers for targeted rehabilitation strategies after breast cancer: Proposal for the next-generation management of survivorship issues

    MARCO INVERNIZZI, NICOLA FUSCO
    BIOCELL, Vol.46, No.10, pp. 2221-2223, 2022, DOI:10.32604/biocell.2022.021043
    (This article belongs to this Special Issue: Recent Advancement in Cancer Molecular Signaling)
    Abstract This article has no abstract. More >

  • Open Access

    ARTICLE

    PI3 kinase isoform p110δ is more important than p110α in KIT signaling in hematopoietic cells

    LIANGYING ZHANG, SHAOTING ZHANG, ZHAOYANG FAN, ZONGYING JIANG, ANBU LIU, SHUJING LI, JIANMIN SUN
    BIOCELL, Vol.46, No.9, pp. 2081-2087, 2022, DOI:10.32604/biocell.2022.020109
    (This article belongs to this Special Issue: Recent Advancement in Cancer Molecular Signaling)
    Abstract PI3 kinases are important for KIT signaling and KIT mutants mediated cell transformation. In order to know the difference of PI3 kinase isoforms p110α and p110δ in the signaling of wild-type KIT and the often occurred KIT mutation D816V in hematopoietic malignancy mastocytosis, the predominant PI3 kinase isoform p110δ in hematopoietic tissues was knocked out in hematopoietic cells. We found that loss of p110δ expression dramatically inhibits PI3 kinase activation mediated by both wild-type KIT and KIT/D816V. By over expression of p110α in p110δ knock out cells, wild-type KIT mediated PI3 kinase activation was not changed while over expression of… More >

  • Open Access

    ARTICLE

    A potential impact of A Disintegrin and Metalloproteinase DomainLike Protein Decysin-1 (ADAMDEC1) on clear cell renal cell carcinoma propagation

    MAGDALENA RUDZIŃSKA-RADECKA
    BIOCELL, Vol.46, No.8, pp. 1893-1901, 2022, DOI:10.32604/biocell.2022.019724
    (This article belongs to this Special Issue: Recent Advancement in Cancer Molecular Signaling)
    Abstract Clear cell renal cell carcinoma (KIRC) is the most common and aggressive malignancy subtype of renal neoplasm that arises from proximal convoluted tubules. It is characterized by poor clinical outcomes and high mortality of patients due to the lack of specific biomarkers for varying stages of the disease and no effective treatment. Proteases are associated with the development of several malignant tumors in humans by their ability to degrade extracellular matrices, facilitating metastasis. Herein, differentially expressed genes in KIRC cases compared to healthy kidneys were screened out from the Gene Expression Profiling Interactive Analysis (GEPIA) database. This data was applied… More >

Share Link

WeChat scan